Evercore ISI is adding Charles River to the firm’s “Tactical Outperform” list ahead of Q2 EPS from the Healthcare Technology & Distribution group. Charles River’s EPS ramp across 2024 is “not appreciated by Street,” says the analyst, who has an Outperform rating and $265 price target on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River to perform plasmid manufacturing for AAVantgarde, no terms
- Nike and Alphabet downgraded: Wall Street’s top analyst calls
- Charles River downgraded to Hold from Buy at Argus
- Charles River initiated with an Equal Weight at Barclays
- Charles River announces strategic collaboration with Gates Institute